Technology
Health
Pharmaceutical

Mitsubishi Tanabe Pharma

$13.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.49 (-3.47%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MTZPY and other stocks, options, ETFs, and crypto commission-free!

About

Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. Read More The company operates through Pharmaceuticals segment. Mitsubishi Tanabe Pharma was founded by Gohei Tanabeya in 1678 and is headquartered in Osaka, Japan. MTZPY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
7,187
Headquarters
Osaka, Osaka
Founded
Market Cap
7.73B
Price-Earnings Ratio
18.10
Dividend Yield
2.15
Average Volume
32.03K
High Today
$13.91
Low Today
$13.72
Open Price
$13.91
Volume
35.55K
52 Week High
$21.43
52 Week Low
$13.69

Collections

Technology
Health
Pharmaceutical
2013 IPO
Asia (Non-China)
Asia

News

BusinessWireMar 18

Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “2018 was a transformational year for Akebia,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. “We successfully executed a number of strategic initiatives to a...

211
The Motley FoolMar 12

Why Akebia Therapeutics Is Soaring Today

What happened Shares of Akebia Therapeutics (NASDAQ:AKBA) were soaring 14.9% higher as of 10:53 a.m. EDT on Tuesday. The biopharmaceutical company announced positive results earlier in the day from two phase 3 clinical studies evaluating vadadustat in treating anemia due to chronic kidney disease (CKD). These studies were conducted by Akebia's commercialization collaboration partner in Japan, Mitsubishi Tanabe Pharma Corporation (MTPC). So what One of the phase 3 clinical studies was conducted on Japanes...

7
ReutersFeb 19

BRIEF-Mitsubishi Tanabe Pharma Says Novartis Pharma Has Filed Request For Arbitration Against It

Feb 20 (Reuters) - Mitsubishi Tanabe Pharma Corp: * SAYS NOVARTIS PHARMA HAS FILED REQUEST FOR ARBITRATION AGAINST IT * NOVARTIS REQUESTS DECLARATION THAT MTPC IS NOT ENTITLED TO CERTAIN ROYALTIES UNDER A PRODUCT SALES AGREEMENT * BELIEVES NOVARTIS SHOULD HONOR AGREEMENT AND WILL OPPOSE NOVARTIS’ REQUEST IN ARBITRATION Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)...

0
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.